|
Press Releases |
|
|
|
Thursday, March 9, 2023 |
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 6, 2023 |
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
Thursday, March 2, 2023 |
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
Tuesday, February 28, 2023 |
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
Tuesday, February 21, 2023 |
|
Dissolution of Bracco-Eisai Joint Venture |
Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. more info >> |
|
Monday, January 30, 2023 |
|
Lecanemab Receives Priority Review Status in Japan |
Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
Friday, January 27, 2023 |
|
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency |
Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline. more info >> |
|
Thursday, January 19, 2023 |
|
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel |
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). more info >> |
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company |
Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
Wednesday, January 18, 2023 |
|
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 |
Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 21:42 JST
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 21, 2024 17:54 HKT/SGT
|
|
|
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 21, 2024 14:14 HKT/SGT
|
|
|
TGL Presented by SoFi Names SYNLawn As Official Synthetic Surface Partner, Providing 31,000 Square Feet of Turf for SoFi Center's Tech-Infused Field of Play
Nov 21, 2024 08:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|